"It would have been important to know that Actos would increase my risks of developing bladder cancer before I began taking it," Whyte says, through the text of a class-action Actos bladder cancer lawsuit in Canada for which he has been proposed as the lead plaintiff. "I believe this class action is necessary to determine whether the manufacturer of this drug should be held responsible for not disclosing such important information to me."
According to Canada NewsWire (7/31/12), Whyte suffers from Type-II diabetes and was prescribed Actos in November 2008. He was diagnosed with bladder cancer in April of this year. Actos has been associated with other Actos side effects, including cardiac events and Actos edema, a condition that affects an individual's eyesight.
However, it is bladder cancer that continues to emerge as the most troubling potential for an Actos adverse reaction. In recent years Actos has grown to be a leading treatment for the management of Type-II diabetes. Patients and doctors alike were buoyed by various studies that suggested Actos was a safer treatment for Type 2 diabetes than the troubled Avandia, manufactured by GlaxoSmithKline.
The latter was at one time the most popular Type-II diabetes drug until it was beset with troubling accusations of heart attack risk and other cardiac events. Actos, manufactured by Takeda Pharmaceuticals, emerged as somewhat of a savior, with heart risks considered not as pronounced as Avandia. Thus, Actos quickly gained a reputation as the safest alternative.
Actos bladder cancer might have been on the horizon, but it had yet to crack any level of public consciousness. And if there was a risk of bladder cancer, consumers didn't appear to know about it.
The Canadian Actos lawsuit, filed in Superior Court in Montreal, holds amongst its allegations that Takeda knew, or should have known that Actos materially increases the risk of bladder cancer, and that the manufacturer failed to disclose such risks in a timely manner.
The Actos bladder cancer lawsuit also holds Takeda accountable for failing to recall Actos.
While adverse reactions such as Actos vision problems remain a viable concern, it is the risk for Actos bladder cancer that concerns the most people. This, after a 2011 study reported to the US food and Drug Administration (FDA) that a clear link had been found between pioglitazone (Actos) and an increased risk for bladder cancer after continual use of Actos for one year.
READ MORE ACTOS SIDE EFFECTS LEGAL NEWS
The study, which was published in June of last year, prompted the FDA to mandate a black box label for Actos with regard to the bladder cancer risk—and the warning has been appearing on the Actos prescribing label for some months.
However, that recent change does not help Actos bladder cancer patients like Whyte, who was prescribed Actos years before the label was updated. In France and Germany, sales of Actos were suspended following publication of the June, 2011 study that established the association between Actos and bladder cancer.